CONFLICTED: Payer Pathways vs Their Own Coverage Policies


CONFLICTED: Payer Pathways vs Their Own Coverage Policies

May 19, 2023

Welcome to the May 2023 edition of our Monthly Insight Series. This month we are examining how Payers’ oncology pathways sometimes conflict with their own coverage policies, and how they can differ but still be aligned from a Payer perspective.

Two hands pulling on a rope in a tug of war.

In 2022, half of our Payer survey participants said they use oncology pathways that restrict physician choice to 1-3 options with the intent to control costs and quality. Most of these Payers (67%) acknowledge that conflicts can (and do) exist between their pathways and their own coverage policies.  An example of this is when a coverage policy restricts a patient from receiving a therapy that is “on pathway.”

Through numerous interviews, we’ve learned that pathway-policy “conflicts” are typically unintentional, and that Payers try to resolve them quickly. 

It’s important to note, however, that our participating plans do not view pathways that simply restrict choice more than their associated drug coverage policies as conflicts:

  • Payers view these policies and pathways as “aligned.” 
  • A Payer may attempt to circumvent Medicare coverage mandates through establishing a favorable coverage policy and then restrict choice of a brand through its pathway program.
  • Payers may seek to enforce their pathways through the prior authorization process, denying an off-pathway selection and forcing either a changed prescription or a “peer-to-peer” discussion before potentially ultimately approving.

So then, we must also ask the questions: What is Payers’ real intent and what is the utility of payer pathways? Are they more analogous to speed limit signs, speed bumps, or traffic lights? HMP Market Access Insights plans to uncover this and much more later this year in our Payer report and in greater depth in our new pathway research program. 

Have some “burning bridge” access questions of your own? Let us know!

All the best . . .

—HMP Market Access Insights Team: Chris, Cindy, Lee, Nandini, and Taylor

The Latest

A stethoscope on a file folder with a line graph superimposed over the image.
IDN Financial Incentives: Impact on Treatment Prices?

Navigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.

Emma Bijesse
A stethoscope on a small pile of dollar bills.
Provider Economics Drive Oncologist Consolidation

Welcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.

Taylor Crutison
Digital graphic of a businessman holding a holographic compass in his palm.
An Update on What You Need to Know About Pathways

Welcome to the February 2024 edition of our Monthly Insight Series, featuring key findings from our recent column in the Journal of Clinical Pathways. The column was the first in a series on oncologists' awareness and use of pathways.

Lee Blansett